Helix BioPharma Reports FY26 Net Loss of $3.35 Million, Cuts R&D 54%
The company reported a $0.04-per-share loss versus $5.21 million in FY25. R&D spending fell 54% to $1.62 million. Cash was $804,000 and its working capital deficit was $4.18 million; the company said funds were insufficient for 12 months and it is seeking financing.
Helix BioPharma reported a FY26 net loss of $3.35M ($0.04/share) vs $5.21M in FY25, with R&D down 54% to $1.62M. Cash was $804K and working capital deficit $4.18M; the company says funds are insufficient for 12 months and seeks financing.Material DetailsContext by AI AnalystThis is an early-stage b…